2,276
Views
14
CrossRef citations to date
0
Altmetric
Articles

Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment

, &
Pages 65-69 | Received 01 Nov 2020, Accepted 05 Jan 2021, Published online: 20 Jan 2021

References

  • Brucker SY, Huebner M, Wallwiener M, et al. Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based study. Fertil Steril. 2014;101(1):237–241.e1.
  • Alvi FA, Glaser LM, Chaudhari A, et al. New paradigms in the conservative surgical and interventional management of adenomyosis. Curr Opin Obstet Gynecol. 2017;29(4):240–248. Aug
  • Struble J, Reid S, Bedaiwy MA. Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol. 2016;23(2):164–185.
  • Hai N, Hou Q, Ding X, et al. Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. Br J Radiol. 2017;90(1069):20160119.
  • Lin XL, Hai N, Zhang J, et al. Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis. Int J Hyperthermia. 2020;37(1):151–156.
  • Nam J-H. Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis. J Obstet Gynaecol Res. 2020;46(1):124–132.
  • Sheng J, Zhang WY, Zhang JP, et al. The LNG-IUS study on adenomyosis: a 3- year follow-up study on the effificacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189–193.
  • Cho S, Nam A, Kim H, et al. Clinical effects of the levonorgestrelreleasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol. 2008;198(4):373. e1–7.
  • Bragheto AM, Caserta N, Bahamondes L, et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007;76(3):195–199.
  • Maheshwari A, Gurunath S, Fatima F, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–392.
  • Rose S, Chaudhari A, Peterson CM. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception. Adv Drug Deliv Rev. 2009;61(10):808–812.
  • Spies JB, Coyne K, Guaou Guaou N, et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99(2):290–300.
  • Sheth SS, Ray SS. Severe adenomyosis and CA125. J Obstet Gynaecol. 2014;34(1):79–81.
  • Abbott JA. Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol. 2017;40:68–81.
  • Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):511–521.
  • Dueholm M. Minimally invasive treatment of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2018;51:119–137.
  • Hai N, Zhang J, Xu R, et al. Percutaneous microwave ablation with artificial ascites for symptomatic uterine adenomyosis: Initial experience. Int J Hyperthermia. 2017;24:1–13.
  • Zhang X, Li K, Xie B, et al. Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound. Int J Gynaecol Obstet. 2014;124(3):207–211.
  • Fan TY, Zhang L, Chen W, et al. Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis. Eur J Radiol 2012;81:3624–3630.
  • Shui L, Mao S, Wu Q, et al. High-intensity focused ultrasound (HIFU) for adenomyosis: two-year follow-up results. Ultrason Sonochem. 2015;27(27):677–681.
  • Louis LS, Saso S, Chatterjee J, et al. Adenomyosis and infertility. Reprod Biomed Online. 2012;24(5):586.
  • Li Q, Yuan M, Li N, et al. The efficacy of medical treatment for adenomyosis after adenomyomectomy. J Obstet Gynaecol Res. 2020;46(10):2092–2099. Oct
  • Pontis A, D’Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696–700.
  • Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010;82(5):396–403.
  • Lin CJ, Hsu TF, Chang YH, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma. Taiwan J Obstet Gynecol. 2018;57(1):47–51. Feb
  • Gao Y, Shan S, Zhao X, et al. Clinical efficacy of adenomyomectomy using H. type incision combined with Mirena in the treatment of adenomyosis. Medicine (Baltimore). 2019;98(11):e14579.
  • Park DS, Kim ML, Song T, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwanese J Obstetr Gynecol. 2015;54(4):412–415.
  • Zhang P, Song K, Li L, et al. Effificacy of combined levonorgestrel releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis. Med Princ Pract 2013;22:480e3.
  • Wall MS, Deng X-H, Torzilli PA, et al. Thermal modification of col- lagen. J Shoulder Elbow Surg. 1999;8:339–344.
  • Moshesh M, Peddada SD, Cooper T, et al. Intraobserver variability in fibroid size measurements: estimated effects on assessing fibroid growth. J Ultrasound Med. 2014;33(7):1217–1224.